期刊文献+

不同浓度伊马替尼对大鼠C6胶质瘤细胞凋亡和细胞周期的影响

Effect of imatinib at different concentrations on rat C6 glioma cell apoptosis and cell cycle
下载PDF
导出
摘要 目的研究伊马替尼对大鼠C6胶质瘤细胞凋亡和细胞周期的影响。方法采用MTT法测定伊马替尼对C6胶质瘤细胞生长曲线的影响。用Hochest/PI染色法和流式细胞仪观察伊马替尼不同浓度(0.156、10和15μmo/L)作用前后,大鼠C6胶质瘤细胞凋亡和细胞周期的变化。结果伊马替尼15μmo/L可显著影响C6胶质瘤细胞的生长曲线。伊马替尼诱导C6细胞凋亡呈时间-剂量依赖性;在72h时间点,10和15μmo/L组G1/G0期细胞比例增加,分别达到(68.53±0.83)%和(70.41±0.62)%(P<0.01);G2期细胞比例分别降至(14.48±0.12)%和(13.84±2.86)%(P<0.01);S期细胞比例分别降至(16.98±0.72)%和(15.78±2.28)%(P<0.01)。结论伊马替尼可诱导大鼠C6胶质瘤细胞凋亡,改变细胞周期的分布。 Objective To investigate the effect of imatinib on rat C6 glioma cell apoptosis and cell cycle. Methods MTT assay was used to determine the OD value of C6 glioma cells following treatment with imatinib at different concentrations (0.156, 10 and 15 μmo/L) for 24, 48 and 72 h. The cell apoptosis was assayed by Hochest/PI staining and the cell cycle changes were analyzed by flow cytometry. Results Imatinib treatment resulted in increased number of apoptotic cells in a timeand dose-dependent manner. A 72-h treatment of the cells with imatinib at 10 and 15 μmo/L caused increased cell percentage in G0/G1 phase to (68.53±0.83)% and (70.41±0.62)%, (P0.01), decreased the percentage of G2phase cells to (14.48±0.12)% and (13.84±2.86)% (P0.01), and decreased the percentage of S phase cells to (16.98±0.72)% and (15.78±2.28)%, respectively (P0.01). Conclusion Imatinib can induce apoptosis and affect the distribution of the cell cycle of C6 cells in vitro.
出处 《南方医科大学学报》 CAS CSCD 北大核心 2010年第5期1089-1091,共3页 Journal of Southern Medical University
关键词 伊马替尼 C6细胞株 细胞凋亡 细胞周期 MTT 胶质瘤 imatinib C6 cells cell apoptosis cell cycle MTT assay glioma
  • 相关文献

参考文献7

  • 1Sawers CL, Hohhasus A, Feldman E, et al. Imatinib induces hematologic and cytigenetic response in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase study[J]. N Engl J Med, 2001, 344(14): 1038-42.
  • 2Cohen MI4, Johnoson JR, Pazdur R_ U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval [ J ]. Clin Cancer Res, 2005, 11: 12-9.
  • 3Dagher R, Cohen M, Williams G, et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors [J]. Clin Cancer Res, 2002, 8: 3034-8.
  • 4Nadal E, Olavarria E. Imatinib mesylate (Gleevec/Glivec) a molecular-targeted therapy for chronic myeloid leukaemia and other malignancies[J]. Int J Clin Pract, 2004,58(5): 511-6.
  • 5Frolov A, Chahwan S, Ochs M, et al. Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors[J]. Mol Cancer Ther, 2003, 2: 699-709.
  • 6Radford IR. Imatinib. Norvartis [J]. Curr Opin Investig Drugs, 2002, 3(3): 492-9.
  • 7Buchdunger E, O'Reilly T. Pharmacology of imatinib (STI571) [J]. Eur J Cancer, 2002, 38: S28-S36.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部